Biocon Mycophenolic Acid gets USFDA okay
New Delhi: Biocon Pharma Limited, a subsidiary of Biocon Limited has received approval from the U S Food and Drug Administration (USFDA) for Mycophenolic Acid.
This product is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. It is available in 180mg and 360mg strengths.
"This approval further adds to Biocon's portfolio of vertically integrated complex drug products," the company said in a BSE filing.
Biocon Limited is an innovation-led global biopharmaceuticals company headquartered in Bangalore. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets, as well as generic formulations in the US and Europe.
Read also: Biocon Biologics, Viatris to offer Insulin Glargine by Walgreens Prescription Savings Club
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd